Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEMETREXED DISODIUM vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
Mesothelioma: In combination with cisplatin for treatment of malignant pleural mesothelioma in patients who are not candidates for curative surgery.,Non-small cell lung cancer: First-line treatment in combination with cisplatin for locally advanced or metastatic nonsquamous NSCLC.,Non-small cell lung cancer: Maintenance monotherapy for locally advanced or metastatic nonsquamous NSCLC with stable disease after 4 cycles of platinum-based chemotherapy.,Non-small cell lung cancer: Second-line treatment as monotherapy for locally advanced or metastatic nonsquamous NSCLC after prior chemotherapy.
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
Terminal half-life is 3.5 hours in patients with normal renal function. Increases in renal impairment (up to 20 hours if Cr Cl <45 m L/min).
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Pemetrexed is primarily eliminated unchanged in urine. It undergoes minimal hepatic metabolism. The drug is a substrate for multidrug resistance-associated proteins (MRPs) and possibly other transporters.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Primarily renal excretion (70-90% as unchanged drug within 24 hours). Biliary/fecal excretion accounts for <5%.
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
~81% bound primarily to albumin.
10-25% bound to albumin at therapeutic concentrations.
Vd = 0.2 L/kg (approximately 16 L in adults). Indicates limited distribution to extravascular spaces.
0.8-1.0 L/kg. Indicates distribution into total body water.
Intravenous: 100% (only route of administration).
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
Cr Cl ≥45 m L/min: No adjustment. Cr Cl <45 m L/min: Not recommended. For Cr Cl 40-59 m L/min, no adjustment; Cr Cl <40 m L/min, not recommended based on clinical trial criteria.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
No specific dose adjustment guidelines for hepatic impairment. Use caution with bilirubin >1.5 times ULN and/or AST/ALT >3 times ULN. Child-Pugh classification not formally studied.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
Safety and efficacy not established in pediatric patients. No recommended dosing.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
No specific dose adjustment recommended based on age alone. Monitor renal function closely as elderly patients may have reduced Cr Cl.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Pemetrexed can cause severe myelosuppression, which may lead to infection and bleeding. Patients must be monitored for bone marrow suppression. Adequate folic acid and vitamin B12 supplementation is required to reduce toxicity.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Bone marrow suppression: Monitor blood counts regularly; dose adjust or hold for severe neutropenia, thrombocytopenia, or anemia.,Renal toxicity: Avoid in creatinine clearance <45 m L/min; monitor renal function.,Gastrointestinal toxicity: Severe diarrhea, mucositis may occur; manage with supportive care.,Dermatologic toxicity: Severe rash may occur; premedicate with corticosteroids.,Radiation recall: Risk of severe radiation recall in patients who have received prior radiotherapy.,Folic acid and vitamin B12 supplementation: Required to reduce hematologic and gastrointestinal toxicity.,Pregnancy: Can cause fetal harm; advise women of reproductive potential to use effective contraception.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
History of severe hypersensitivity reaction to pemetrexed or any excipient.,Patients with creatinine clearance <45 m L/min (contraindicated for use in combination with cisplatin due to increased toxicity).
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
No known food interactions. Avoid folic acid-containing supplements beyond prescribed dose as they may interfere with pemetrexed activity. Maintain adequate hydration.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
Pemetrexed is contraindicated in pregnancy. It is an antifolate antimetabolite that inhibits thymidylate synthase and other folate-dependent enzymes, essential for DNA synthesis and cell division. Based on its mechanism of action and animal studies, it is expected to cause fetal harm when administered to a pregnant woman. First trimester: High risk of teratogenicity (neural tube defects, craniofacial, cardiovascular malformations) due to folate antagonism. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal death. Embryofetal toxicity and teratogenicity have been demonstrated in mice and rats at doses lower than the human therapeutic dose.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
No data available on the presence of pemetrexed in human milk, its effects on the breastfed infant, or on milk production. Due to the potential for serious adverse reactions in the breastfed infant (including myelosuppression, gastrointestinal toxicity, and carcinogenesis), breastfeeding is not recommended during therapy and for at least 1 week after the last dose. The M/P ratio is unknown.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No specific dose adjustment guidelines exist for pemetrexed in pregnancy because its use is contraindicated. However, pregnancy may alter the pharmacokinetics of pemetrexed due to increased renal clearance (increased glomerular filtration rate) and expanded plasma volume, potentially reducing drug exposure. No formal studies have been conducted. Given the high risk of fetal harm, pemetrexed should not be used in pregnant women. If treatment is deemed necessary for a life-threatening condition, the risks versus benefits must be considered, and dosing adjustments cannot be recommended due to lack of data.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
Administer folic acid 350-1000 mcg orally daily beginning 7 days before first dose and continuing throughout therapy. Administer vitamin B12 1000 mcg IM 1 week before first dose and every 3 cycles thereafter. Premedicate with dexamethasone 4 mg orally twice daily the day before, day of, and day after each dose to reduce cutaneous reactions. Monitor for myelosuppression, especially neutropenia; dose reduce as needed. Contraindicated in patients with creatinine clearance <45 m L/min. Avoid NSAIDs 2-5 days before and 2 days after pemetrexed due to increased toxicity.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Take folic acid supplements daily, starting 7 days before your first treatment and continuing until your doctor stops it.,You will receive vitamin B12 injections before your first dose and then every 9 weeks.,Take a steroid medication (dexamethasone) as prescribed the day before, day of, and day after each infusion to prevent skin reactions.,Avoid taking NSAIDs (like ibuprofen or naproxen) for at least 2-5 days before and 2 days after your pemetrexed infusion.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or severe fatigue immediately.,Drink plenty of fluids unless otherwise instructed. There are no specific dietary restrictions, but maintain a balanced diet.,Use effective contraception during treatment and for at least 6 months after the last dose (females) or 3 months (males). Do not breastfeed during treatment.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
"The risk or severity of adverse effects can be increased when Pemetrexed is combined with Leflunomide."
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
"Pemetrexed may increase the immunosuppressive activities of Fingolimod."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEMETREXED DISODIUM vs OFIRMEV, answered by our medical review team.
PEMETREXED DISODIUM is a Antineoplastic Antifolate that works by Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEMETREXED DISODIUM and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEMETREXED DISODIUM is: 500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEMETREXED DISODIUM and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEMETREXED DISODIUM is classified as Category C. Pemetrexed is contraindicated in pregnancy. It is an antifolate antimetabolite that inhibits thymidylate synthase and other folate-dependent enzymes, essential for DNA synthesis an. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.